No Data
CT ENTERPRISE (03839.HK) plans to hold a Board of Directors meeting on February 24 to approve its annual performance.
On February 10, Gelonghui reported that CT ENTERPRISE (03839.HK) announced that the Board of Directors will hold a meeting on February 24, 2025 (Monday) to approve the annual performance of the company and its subsidiaries for the year ended December 31, 2024, and to consider the distribution of a final dividend (if any).
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Chia Tai Enterprises International Expects Higher Attributable Profit in 2024
CT ENTERPRISE (03839.HK) announces good news: it is expected that the consolidated profit attributable to Shareholders in 2024 will be approximately 11 million US dollars.
On January 22, Glonghui announced that CT ENTERPRISE (03839.HK) expects to record a consolidated profit attributable to Shareholders of approximately 11 million USD for the financial year ending December 31, 2024, compared to 2.6 million USD for the financial year ending December 31, 2023. The increase in profit is mainly due to the improved performance of the Group's biochemical Business, however, the profit attributable to the Group's industrial Business is expected to decline due to fierce competition.
CT ENTERPRISE: Positive Profit Alert
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Not Many Are Piling Into Chia Tai Enterprises International Limited (HKG:3839) Stock Yet As It Plummets 26%
